Raptor Pharma (RPTP) Tops Q4 EPS by 1c

Raptor Pharma (NASDAQ: RPTP) reported Q4 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $21 million versus the consensus estimate of $26.08 million.

GUIDANCE:

Raptor Pharma sees FY2016 revenue of $115-125 million.

• Expecting PROCYSBI revenue growth of 25%-30%, assuming the mid- to high-point of the total revenue guidance range.
• Establishing non-GAAP operating expense guidance, excluding non-cash stock-based compensation expense, of $135 to $145 million.

For earnings history and earnings-related data on Raptor Pharma (RPTP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c